Outcome of Board Meeting
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eyantra Ventures' Board approved standalone and consolidated unaudited results for Q2 FY26 and H1 FY26. Standalone revenue surged to ₹1,819.59 lakhs in Q2 FY26 from ₹635.51 lakhs in Q2 FY25, a jump of about 186%. However, standalone net profit fell sharply to ₹4.35 lakhs from ₹34.41 lakhs due to higher purchase and employee costs. On a consolidated basis, revenue was ₹2,294.86 lakhs but the company swung to a net loss of ₹425.53 lakhs in Q2 FY26 versus a profit of ₹34.18 lakhs a year ago, largely dragged by its newly consolidated subsidiary Neuro and Spine Associates, which reported a loss of ₹336.54 lakhs for the quarter. H1 FY26 consolidated net loss stood at ₹785.15 lakhs. The auditor (PRSV & Co LLP) issued an unmodified limited review report.
Strong top-line growth from business expansion and the Neuro and Spine Associates acquisition is positive, but sharply falling margins, consolidated losses, and negative operating cash flows (-₹727 lakhs standalone, -₹1,254 lakhs consolidated) are concerns. Shareholders should watch whether the healthcare subsidiary can turn profitable, as it currently dominates the consolidated loss.